Skip to main content
Clinical Trials/NCT05252130
NCT05252130
Completed
Not Applicable

Comparison of NoaScope to the Conventional Stethoscope for Auscultation of Heart and Lung Sounds

Innova Smart Technologies (Pvt.) Ltd1 site in 1 country47 target enrollmentDecember 22, 2021
ConditionsChest Pathology

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Chest Pathology
Sponsor
Innova Smart Technologies (Pvt.) Ltd
Enrollment
47
Locations
1
Primary Endpoint
The measurement of sound quality in a clinical setting by means of an MOS scale on a questionnaire.
Status
Completed
Last Updated
3 years ago

Overview

Brief Summary

Assessing non-inferiority of a newly developed electronic stethoscope NoaScope in comparison with the conventional 3M Littmann stethoscope

Detailed Description

The enrolled population will include adults with a history of heart and lung complications. The enhanced sound quality of the electronic stethoscope and its non-inferiority to the traditional/conventional 3M Littmann stethoscope will be assessed through auscultation examination of every patient by a health professional (consultant, medical resident, and house officer) with both the electronic stethoscope and 3M Littmann/traditional/conventional stethoscope

Registry
clinicaltrials.gov
Start Date
December 22, 2021
End Date
February 10, 2022
Last Updated
3 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Sponsor
Innova Smart Technologies (Pvt.) Ltd
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Ages: 18 years or older (male and female)
  • Hospital admitted or Out Patient Department
  • Written consent provided

Exclusion Criteria

  • ICU admitted
  • Written consent not provided

Outcomes

Primary Outcomes

The measurement of sound quality in a clinical setting by means of an MOS scale on a questionnaire.

Time Frame: 1 month

The investigators will measure sound quality on a mean opinion score scale with values ranging form 1 (bad) to 5 (excellent).

Correctly identified abnormal heart and lung sounds by doctors using two stethoscopes: NoaScope and 3M™️ Littmann®️ Classic III.

Time Frame: 1 month

Each patient will receive two auscultation examinations: one with NoaScope and another with 3M™️ Littmann®️ Classic III. The investigators will determine the clinical feasibility and non-inferiority of NoaScope to the FDA-approved 3M™️ Littmann®️ Classic III from auscultation findings (heart and lungs) by doctors (holding varied levels of clinical expertise). Doctors will examine each patient using two stethoscopes: NoaScope and 3M™️ Littmann®️ Classic III. The investigators will also measure inter and intra observer agreement by the Kappa index with the help of a questionnaire. Kappa values \< 0.8 means weak to moderate level of agreement and Kappa values between 0.8 - 1.0 would mean strong level of agreement.

Secondary Outcomes

  • Difference in performance between subgroups of doctors based on clinical experience.(1 month)

Study Sites (1)

Loading locations...

Similar Trials